The countrywide vaccination drive was rolled out on January 16 last year with healthcare workers getting inoculated in the first phase. Vaccination of frontline workers started from February 2 last year.
Covaxin was assessed under the WHO EUL procedure based on the review of data on quality, safety, efficacy, a risk management plan and programmatic suitability.
India recently surpassed the milestone of administering 100 crore doses of Covid-19 vaccines and Bharat Biotech’s Covaxin undoubtedly has been an integral part of this journey.
"We are keeping our preparations ready. So far, we are saved from this (Omicron) threat," he said, adding "our effort is to provide the best possible (medical) services to the people".
The Technical Advisory Group (TAG) on October 26 had sought 'additional clarifications' from the company for Covaxin to conduct a final 'risk-benefit assessment' for Emergency Use Listing of the vaccine.
The submission is based on results of Bharat Biotech's Phase 2/3 paediatric clinical trial involving 526 children between 2-18 years of age.